Fierce Biotech2h
Vertex abandons islet cell-device combo after failing to improve diabetes biomarker
Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...
Vertex Pharmaceuticals says VX-264 study did not meet primary endpoint
Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...